Amended Statement of Ownership (sc 13g/a)
May 20 2015 - 4:20PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment
No. 1)*
IMPRIMIS
PHARMACEUTICALS, INC.
(Name
of Issuer)
Common
Stock, $0.001 par value
(Title
of Class of Securities)
45323A
201
(CUSIP
Number)
May
18, 2015
(Date
of Event Which Requires Filing of this Statement)
Check the
appropriate box to designate the rule pursuant to which this Schedule is filed:
|
[ ] |
Rule
13d-1(b) |
|
[X] |
Rule 13d-1(c) |
|
[ ] |
Rule 13d-1(d) |
*The remainder
of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior
cover page.
The information
required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).
CUSIP
No. 45323A 201 |
13G |
Page
2 of 5 Pages |
1. |
Names of Reporting
Persons. |
|
|
|
Donald Miloni |
|
|
2. |
Check the Appropriate
Box if a Member of a Group (see instructions) |
|
(a)
[ ] |
|
(b)
[ ] |
3. |
SEC Use Only |
|
|
4 |
Citizenship
or Place of Organization
|
|
|
|
U.S.A |
Number
of Shares
Beneficially
Owned by
Each Reporting
Person With: |
5.
Sole Voting Power
468,5761
|
6.
Shared Voting Power
278,4792
|
7.
Sole Dispositive Power
468,5761
|
8.
Shared Dispositive Power
278,4792 |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
747,0553
|
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(see instructions)
[ ]
|
11. |
Percent of Class Represented by Amount in Row 9
7.82%4
|
12. |
Type of Reporting Person (see instructions)
IN |
1
Includes 468,576 shares of the Issuer’s common stock held in the name of the person filing this Schedule 13G.
2
Includes (i) 25,316 shares of the Issuer’s common stock held in the name of the spouse of the person filing this
Schedule 13G, (ii) 151,898, shares of the Issuer’s common stock held in the name of 1425 Greenwood Lane, LLC, of which
the person filing this Schedule 13G is a managing member, and (iii) 101,265 shares of the Issuer’s common stock held
in the name of RCHER Financial, LLC, of which the person filing this Schedule 13G is a managing member.
3
Consists of the securities set forth in footnotes (1) and (2) above. The person filing this Schedule 13G disclaims beneficial
ownership of these securities except to the extent of his pecuniary interest therein.
4
The percentage was calculated based on 9,511,026 shares of the Issuer’s common stock outstanding as of May 13, 2015.
CUSIP
No. 45323A 201 |
13G |
Page
3 of 5 Pages |
Item 1(a). |
Name of Issuer: |
Imprimis
Pharmaceuticals, Inc.
Item
1(b). |
Address
of Issuer’s Principal Executive Offices: |
12264
El Camino Real, Suite 350
San
Diego, CA 92130
Item
2(a). |
Name
of Person Filing: |
Donald
Miloni
Item
2(b). |
Address
of Principal Business Office, or if None, Residence: |
1425
Greenwood Lane
Greenwood
Village, CO 80125
U.S.A.
Item
2(d). |
Title
of Class of Securities: |
Common
Stock, par value $0.001
45323A
201
Item
3. |
If
this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is
a: |
Not
applicable
Provide
the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in
Item 1.
|
(a) |
Amount
beneficially owned: |
747,055*
7.82%
|
(c) |
Number
of shares as to which such person has: |
|
(i) |
Sole
power to vote or to direct the vote |
468,576*
CUSIP
No. 45323A 201 |
13G |
Page
4 of 5 Pages |
|
(ii) |
Shared
power to vote or to direct the vote |
278,479*
(Includes (i) 25,316 shares of the Issuer’s common stock held in the name of the spouse of the person filing this Schedule
13G, (ii) 151,898, shares of the Issuer’s common stock held in the name of 1425 Greenwood Lane, LLC, of which the person
filing this Schedule 13G is a managing member, and (iii) 101,265 shares of the Issuer’s common stock held in the name of
RCHER Financial, LLC, of which the person filing this Schedule 13G is a managing member.)
|
(iii) |
Sole
power to dispose or to direct the disposition of |
468,576*
|
(iv) |
Shared
power to dispose or to direct the disposition of |
278,479*
(Includes (i) 25,316 shares of the Issuer’s common stock held in the name of the spouse of the person filing this Schedule
13G, (ii) 151,898, shares of the Issuer’s common stock held in the name of 1425 Greenwood Lane, LLC, of which the person
filing this Schedule 13G is a managing member, and (iii) 101,265 shares of the Issuer’s common stock held in the name of
RCHER Financial, LLC, of which the person filing this Schedule 13G is a managing member.)
*
The person filing this Schedule 13G disclaims beneficial ownership of these securities except to the extent of his pecuniary interest
therein.
Item
5. |
Ownership
of Five Percent or Less of a Class. |
Not
Applicable.
Item
6. |
Ownership
of More Than Five Percent on Behalf of Another Person. |
Not
Applicable.
Item
7. |
Identification
and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. |
Not
Applicable.
Item
8. |
Identification
and Classification of Members of the Group. |
Not
Applicable.
Item
9. |
Notice
of Dissolution of the Group. |
Not
Applicable.
Item
10. Certification.
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than
activities solely in connection with a nomination under § 240.14a-11.
CUSIP
No. 45323A 201 |
13G |
Page
5 of 5 Pages |
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated:
May 20, 2015 |
DONALD
MILONI |
|
|
|
By: |
/s/
Donald Miloni |
|
|
Donald
Miloni, an individual |
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From Jul 2023 to Jul 2024